« Malaria, asplenia : a story of sensing, swelling, sickling & pitting »
« Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses »
The effectiveness of a vaccine against #HIV
Dr behazine combadière, a lead investigator at the centre for immunology and infectious diseases @inserm is working on predicting the effectiveness of a vaccine against #hiv which is concurrently advancing the #covidvaccine development research.
Vaccine responses against SARS-CoV-2 variants examined in people with lupus
The majority of people with systemic lupus erythematosus (SLE) who respond to messenger (m)RNA COVID-19 vaccines also generate an antibody response against emerging SARS-CoV-2 variants, albeit with reduced neutralizing activity against variants bearing the E484K mutation, researchers report.
A personalized precision medicine approach is needed to treat Covid-19 as more than one type of “Cytokine storm” is induced by SARS-CoV-2
The severe form of Covid-19 is known to be associated with the excessive elevation of many cytokines, a condition termed “cytokine storm”. Therapy with biological agents intended to block these cytokines, for example anti-interleukin-6 or anti-interleukin-1 antibodies, was already tried, albeit with a limited success.
Residency and trafficking of ILC2 under stable and Th2-induced inflammatory conditions
Is it dangerous to be vaccinated if you have already had the coronavirus?
A message received by the editorial staff of LCI.fr is concerned about the possible danger of a vaccine against Covid-19 for people already infected. We respond with Béhazine Combadière, director of research at Inserm.
Covid-19: a needle-free vaccination soon possible?
To meet the demand for vaccines, and to avoid a possible shortage of needles and syringes, start-ups, with the support of certain countries such as Canada, are working on injection methods that are not intramuscular, but through the skin.
Particularly active antibodies as a barrier to SARS-CoV-2
Teams from the Pitié-Salpêtrière AP-HP hospital, Sorbonne University, Inserm and the Pasteur Institute have carried out work to study the role played by IgA-type antibodies in protecting the body against Covid-19 in the mucous membranes, particularly the respiratory tract.